Endo Pharmaceuticals (NAS: ENDP) came in right in line with the Street's expectations last quarter, but investors are hoping that it will beat them this quarter. The company will unveil its latest earnings on Tuesday, August 9. Endo Pharmaceutical Holdings is a specialty pharmaceutical company, which is engaged in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain.
What analysts say:
What our community says:
CAPS All-Stars are solidly behind the stock, with 99.4% awarding it an "outperform" rating. The community at large backs the All-Stars, with 96.2% giving it a rating of "outperform." Fools are keen on Endo Pharmaceuticals and haven't been shy with their opinions lately, logging 168 posts in the past 30 days. Endo Pharmaceuticals has a bullish CAPS rating of five out of five stars, echoing the Fool community sentiment.
Endo Pharmaceuticals' profit has risen year over year by an average of 9.1%. Revenue has now gone up for three straight quarters. The company's gross margin shrank by 15.5 percentage points in the last quarter. Revenue rose 53.7% while cost of sales rose 146.1% to $231.6 million from a year earlier.
Now let's look at how efficient management is at running the business. Traditionally, margins represent the efficiency with which companies capture portions of sales dollars. The following table shows gross, operating, and net margins over the past four quarters.
For all our Endo Pharmaceuticals-specific analysis, including earnings and beyond, add Endo Pharmaceuticals to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
At the time thisarticle was published
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.